Novel agents in the management of castration resistant prostate cancer

Chaturvedi, Shruti; Garcia, Jorge A.
January 2014
Journal of Carcinogenesis;2014, Vol. 13 Issue 1, p1
Academic Journal
Prostate cancer (PCa) is a leading cause of cancer mortality in men and despite high cure rates with surgery and/or radiation, 30-40% of patients will eventually develop advanced disease. Androgen deprivation is the first line therapy for standard of care for men with advanced disease. Eventually however all men will progress to castration-resistant prostate cancer (CRPC). Insight into the molecular mechanisms of androgen resistance has led to the development of alternative novel hormonal agents. Newer hormonal agents such as abiraterone, enzalutamide and TOK-001; and the first cancer vaccine, Sipuleucel T have been approved for use in men with CRPC. The recognition of the importance of bone health and morbidity associated with skeletal related events has led to the introduction of the receptor activator of nuclear factor kappa-B-ligand inhibitor denosumab. Other molecularly targeted therapies have shown promise in pre-clinical studies, but this has not consistently translated into clinical efficacy. It is increasingly evident that CRPC is a heterogeneous disease and an individualized approach directed at identifying primary involvement of specific pathways could maximize the benefit from targeted therapies. This review focuses on targeted therapy for PCa with special emphasis on therapies that have been Food and Drug Administration approved for use in men with CRPC.


Related Articles

  • Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer. Hoffman, Richard M.; Koyama, Tatsuki; Kang-Hsien Fan; Albertsen, Peter C.; Barry, Michael J.; Goodman, Michael; Hamilton, Ann S.; Potosky, Arnold L.; Stanford, Janet L.; Stroup, Antoinette M.; Penson, David F. // JNCI: Journal of the National Cancer Institute;5/15/2013, Vol. 105 Issue 10, p711 

    Background No randomized trials have compared survival outcomes for men with localized prostate cancer (PC) being treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT). The goal of the study, therefore, was to estimate the association of RP (compared with EBRT) with...

  • Sipuleucel-T (Provenge)-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. Jarosławski, Szymon; Toumi, Mondher // BioDrugs;Oct2015, Vol. 29 Issue 5, p301 

    Approved by the US Food and Drug Administration (FDA) in 2010, sipuleucel-T (Provenge) was the first 'personalized' cancer vaccine for the treatment of prostate cancer in a metastatic, non-symptomatic population of 30,000 men in the USA. Sipuleucel-T is prepared individually for each patient and...

  • A changing landscape in castration-resistant prostate cancer treatment. Felici, A.; Pino, M. S.; Carlini, Paolo // Frontiers in Endocrinology;Jul2012, Vol. 3, p1 

    Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10-20% of men with PC present with metastatic disease at diagnosis, while 20-30% of patients diagnosed with localized disease will eventually develop metastases....

  • Sipuleucel-T Retreatment May Benefit Patients with mCRPC. SCHIESZER, JOHN // Renal & Urology News;Jul2013, Vol. 12 Issue 7, p21 

    The article focuses on a study presented at the 2013 American Society of Clinical Oncology annual meeting on the safety and benefit of sipuleucel-T (Provenge) retreatment, an autologous cellular immunotherapy, on patients with metastatic castrationresistant prostate cancer (mCRPC).

  • Erratum:.  // JNCI: Journal of the National Cancer Institute;Nov2014, Vol. 106 Issue 11, p1 

    A correction to the article "Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer" which appeared in a previous issue is presented.

  • Focal cryosurgical ablation of the prostate: a single institute's perspective. Hale, Zachary; Miyake, Makito; Palacios, Diego Aguilar; Rosser, Charles J. // BMC Urology;2013, Vol. 13 Issue 1, p1 

    Background: With the stage migration of prostate cancer witnessed in the late 1990's and early 2000's along with the persistent morbidities associated with prostatectomy and radiation therapy, the concept of focal prostate cancer treatment remains quite attractive. Herein we evaluate the...

  • Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. Lohm, Gunnar; Bottke, Dirk; Jamil, Basil; Miller, Kurt; Neumann, Konrad; Bartkowiak, Detlef; Hinkelbein, Wolfgang; Wiegel, Thomas // World Journal of Urology;Apr2013, Vol. 31 Issue 2, p423 

    Purpose: Salvage radiotherapy (SRT) is applied routinely in patients with a biochemical relapse after radical prostatectomy (RP). Although the detection threshold for relapse after RP has steadily been lowered, only about 30 % of the SRT patients achieve a durable response. We have previously...

  • Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy. Bermejo, Carlos; Kristal, Alan R.; Zeliadt, Steven B.; Ramsey, Scott; Thompson, Ian M. // JNCI: Journal of the National Cancer Institute;9/15/2004, Vol. 96 Issue 18, p1348 

    Editorial. Focuses on the growing evidence of side-effects from prostate cancer treatment in the United States. Outcomes of radical prostatectomy and radiotherapy; Prostate cancer screening with the prostate-specific antigen; Long-term morbidity of prostate cancer treatment.

  • Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial. Xia, Jing; Gulati, Roman; Au, Margaret; Gore, John L.; Lin, Daniel W.; Etzioni, Ruth // JNCI: Journal of the National Cancer Institute;4/17/2013, Vol. 105 Issue 8, p546 

    Background The Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) trial showed that radical prostatectomy (RP) reduced prostate cancer deaths with an absolute mortality difference (AMD) between the RP and watchful waiting arms of 6.1% (95% confidence interval [CI] = 0.2% to 12.0%) after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics